GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vista Pharmaceuticals Ltd (BOM:524711) » Definitions » EV-to-EBITDA

Vista Pharmaceuticals (BOM:524711) EV-to-EBITDA : -10.79 (As of May. 30, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Vista Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vista Pharmaceuticals's enterprise value is ₹740.24 Mil. Vista Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₹-68.62 Mil. Therefore, Vista Pharmaceuticals's EV-to-EBITDA for today is -10.79.

The historical rank and industry rank for Vista Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

BOM:524711' s EV-to-EBITDA Range Over the Past 10 Years
Min: -227.11   Med: 6.98   Max: 96.09
Current: -10.78

During the past 13 years, the highest EV-to-EBITDA of Vista Pharmaceuticals was 96.09. The lowest was -227.11. And the median was 6.98.

BOM:524711's EV-to-EBITDA is ranked worse than
100% of 714 companies
in the Drug Manufacturers industry
Industry Median: 14.545 vs BOM:524711: -10.78

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-30), Vista Pharmaceuticals's stock price is ₹13.39. Vista Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹-2.020. Therefore, Vista Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Vista Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Vista Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vista Pharmaceuticals EV-to-EBITDA Chart

Vista Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.74 -25.62 -28.53 -42.09 -10.44

Vista Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -58.79 -10.44 -9.26 -15.76 -10.03

Competitive Comparison of Vista Pharmaceuticals's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Vista Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vista Pharmaceuticals's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vista Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Vista Pharmaceuticals's EV-to-EBITDA falls into.



Vista Pharmaceuticals EV-to-EBITDA Calculation

Vista Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=740.236/-68.62
=-10.79

Vista Pharmaceuticals's current Enterprise Value is ₹740.24 Mil.
Vista Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-68.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vista Pharmaceuticals  (BOM:524711) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Vista Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.39/-2.020
=At Loss

Vista Pharmaceuticals's share price for today is ₹13.39.
Vista Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-2.020.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Vista Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Vista Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Vista Pharmaceuticals (BOM:524711) Business Description

Traded in Other Exchanges
N/A
Address
Plot No. 104, Kakateeya Hills, Ravindra Co OP Society Guttala Begumpet, Hyderabad, TG, IND, 500033
Vista Pharmaceuticals Ltd is an Indian based company engaged in single operating segments that is the manufacturing of Pharmaceutical products. The company offers over the counter and prescription generic drug products such as tablets, capsules, and liquids covering various therapeutic categories. Some of the drugs in tablet dosage forms are Sulfamethoxazole and Trimethoprim, Bismuth Subgallate, Pyrantel Pamoate, Aspirin, Ibuprofen, Ranitidine HCl, and others. Nifedipine, Piroxicam, Indomethacin are the drugs offered by the company in a capsule dosage form. The business is carried out in India.

Vista Pharmaceuticals (BOM:524711) Headlines

No Headlines